- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04514692
Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF and FDG-PET Imaging
Phase 1 2 Study of Individualized Bone Marrow Sparing Image Guided Radiotherapy Incorporating Novel Use of Granulocyte Colony Stimulating Factor and FDG PET Imaging
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a phase 1 and 2 study. The phase I is a dose finding portion of the study and phase 2 will enroll additional patients at the dose found in phase I. Patients in phase I and phase 2 will have the same treatment and followup.
Participants will undergo standard of care diagnostic imaging, complete blood count (CBC) with differential and chemistry labs initially. While receiving the GCSF, participants will have a CBC with differential checked a day after each dose and one day prior to first day of radiation. The treatment planning FDG PET/CT will be performed shortly after the GCSF. During chemoradiation, participants will have weekly CBC with differential checked and other labs as standard of care.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Camellia Djebroun
- Phone Number: 650-721-4076
- Email: cdjebrou@stanford.edu
Study Locations
-
-
California
-
Stanford, California, United States, 94034
- Recruiting
- Stanford Cancer Institute Palo Alto
-
Contact:
- Camellia Djebroun
- Phone Number: 650-721-4076
- Email: cdjebrou@stanford.edu
-
Principal Investigator:
- Elizabeth A Kidd
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 2018 international Federation of Gynecology and Obstetrics (FIGO) stage I IIIC1 cervix cancer with no prior treatment or stage IIIA IIIC1 endometrial cancer status post hysterectomy and lymph node assessment
- No required para aortic or extended field radiation
- Eastern Cooperative Oncology Group (ECOG) performance status 0 2
- Adequate kidney function (serum Cr <1.5 or creatinine clearance >50 mg/dl)
- Adequate bone marrow function (white blood cells > 3.0 X 109/L, platelets >100 x 109/L)
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Treatment for other cancer in the past 2 years
- Previous pelvic radiation
- Medical condition that prevents receiving chemotherapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase I -Dose finding, Cohort 1
Dosing will occur in cohorts of 4 patients with the start at dose of GCSF will be 780 mcg x 3 days
|
Fluorodeoxyglucose (FDG)-positron emission tomography (PET) and computed tomography (CT)
Granulocyte Colony Stimulating Factor (GCSF)
Other Names:
|
Experimental: Phase I -Dose finding, Cohort 2
Dosing will occur in cohorts of 4 patients, If 4 out of 4 patients achieve the target SUVmean, the GCSF dose will be 780 mcg x 2 days
|
Fluorodeoxyglucose (FDG)-positron emission tomography (PET) and computed tomography (CT)
Granulocyte Colony Stimulating Factor (GCSF)
Other Names:
|
Experimental: Phase I -Dose finding, Cohort 3
Dosing will occur in cohorts of 4 patients, If 4 out of 4 patients achieve the target SUVmean, the GCSF dose will be 780 mcg x 1 day
|
Fluorodeoxyglucose (FDG)-positron emission tomography (PET) and computed tomography (CT)
Granulocyte Colony Stimulating Factor (GCSF)
Other Names:
|
Experimental: Phase II-G-CSF
Phase 2 participants will be treated with the optimal dose of GCSF found in the phase 1 portion of the study.
|
Fluorodeoxyglucose (FDG)-positron emission tomography (PET) and computed tomography (CT)
Granulocyte Colony Stimulating Factor (GCSF)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determine the Recommended phase 2 dose (RP2D)
Time Frame: 12 months
|
Recommended phase 2 dose (RP2D) will be defined as the dose at which the standard uptake value (SUV) on D5 FDG PET reaches target SUVmean of 2.5 or higher with normalization of white blood cells (WBC) and ANC prior to start of radiation.
|
12 months
|
Determine the rate of grade 3 or greater neutropenia (ANC < 1000/mm3 at any point of therapy)
Time Frame: 33 months
|
Rate of grade 3 or greater neutropenia (ANC < 1000/mm3 at any point of therapy) will be monitored by the regular CBC with differential on the study schema and calendar, as per standard of care for patients receiving chemoradiation and/or chemotherapy.
|
33 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Elizabeth A Kidd, Stanford Universiy
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB-56842
- GYN0007 (Other Identifier: OnCore)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cervix Cancer
-
Tata Memorial HospitalCompleted
-
Fatma Ahmed Abdelfatah RikabeSohag UniversityNot yet recruiting
-
University of New MexicoTerminated
-
Tata Memorial HospitalCompletedCervical Cancer | Cervix Cancer | Cancer of Cervix | Cancer of the CervixIndia
-
Taipei Medical UniversityUnknownSmoking | Precancerous Lesions | Cancer Cervix UterusTaiwan
-
Tehran University of Medical SciencesRecruitingCervix Uteri CancerIran, Islamic Republic of
-
Banaras Hindu UniversityCompletedCervical Cancer | Cervix Cancer | Cancer of the Uterine CervixIndia
-
Abramson Cancer Center of the University of PennsylvaniaCompletedUterine Cervix CancerUnited States
-
University Hospital, ToursCompleted
-
Eli Lilly and CompanyCompletedCancer of CervixMexico, Thailand, Argentina, Bosnia and Herzegovina, India, Pakistan, Peru
Clinical Trials on FDG PET/CT
-
Washington University School of MedicineTerminatedCervical Cancer | Uterine Cervical Neoplasms | Uterine Cervical CancerUnited States
-
University of UtahNational Cancer Institute (NCI)CompletedFluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) in Cancer Associated VenothromboembolismVenothromboembolismUnited States
-
Peter MacCallum Cancer Centre, AustraliaMelbourne Health; Westmead Hospital; Victorian Infectious Diseases Reference...CompletedAcute Myeloid Leukemia | Febrile Neutropenia | Acute Lymphoblastic Leukemia | Haematopoietic Stem Cell Transplant, Autologous | Haematopoietic Stem Cell Transplant, AllogeneicAustralia
-
Region VästerbottenUmeå UniversityRecruitingCervix Cancer | Endometrial Cancer | Epithelial Ovarian CancerSweden
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedMalignant Neoplasm of Breast TNM Staging Distant Metastasis (M) | Untreated Bone MetastasesUnited States
-
Abramson Cancer Center at Penn MedicineActive, not recruiting
-
University of ZurichWithdrawnAdenocarcinoma | Stomach Cancer | Cancer of Esophagogastric JunctionSwitzerland
-
Rabin Medical CenterUnknown
-
Ontario Clinical Oncology Group (OCOG)Cancer Care OntarioActive, not recruitingMuscle-invasive Bladder CancerCanada